Dyne Therapeutics, Inc. research snapshot
DYN AI stock analysis reads Dyne Therapeutics as a high-risk, high-reward clinical-stage biotechnology company focused on muscle diseases using its proprietary FORCE platform. The stock has rallied sharply from its $8.24 52-week low to near $23.42 as of the July 12, 2026 data cutoff, driven by completed enrollment in the registrational expansion cohort of the ACHIEVE trial for DYNE-101 in myotonic dystrophy type 1 (DM1). With a verified market capitalization near $3.87 billion, Dyne holds approximately $972 million in cash with access to a $400 million debt facility, extending its runway into 2028. This page uses scenario ranges and source checks, not a certain stock price prediction, and is for informational use only.
Current price
$23.42
Market cap
$3.87 billion
AI score
55 / 100
Rating
Clinical-stage neuromuscular biotech with late-stage DM1 catalyst, high cash burn, binary trial risk
Trend status
Strong uptrend from $8.24 52-week low, near all-time highs after ACHIEVE trial enrollment completion
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Dyne is a pre-commercial biotechnology company building antibody-oligonucleotide conjugates (AOCs) for muscle diseases. Business quality is unproven until clinical efficacy, safety, regulatory approval, and commercial adoption are demonstrated. | Low |
| Moat | Dynes FORCE platform uses antibody-mediated delivery to target muscle tissue, which differentiates it from unconjugated oligonucleotide therapies. If clinical data confirms superior muscle delivery and efficacy, the platform could be a meaningful competitive asset against Ionis, Sarepta, Avidity, and PepGen. | Low-medium |
| Management | Management has achieved key enrollment milestones for the ACHIEVE trial, secured an expanded $400 million debt facility, and appointed industry veteran Barry Greene to the board. The team should be judged on clinical execution, regulatory strategy, capital management, and eventual commercial preparation. | Medium |
| Financial trend | Dyne has no revenue and generates GAAP net losses of roughly $110 million to $120 million per quarter. Cash and equivalents of $972 million plus a $400 million debt facility provide runway into 2028, but the company remains dependent on equity or debt markets for long-term funding. | High |
| Valuation | At $23.42 and $3.87 billion market cap, Dyne trades at a premium to cash value (~$972M cash / 165M shares = ~$5.88 per share), meaning the market assigns roughly $17.54 per share in pipeline value. This is typical for a late-stage biotech with a registrational catalyst but prices in significant success probability. | Medium |
| Technical trend | DYN has been in a strong uptrend since early 2026, rallying from $8.24 to near $25.00. The stock is near its 52-week high and above all major moving averages. Momentum is strong but the stock is extended, making it sensitive to any news flow. | Medium |
| Risk level | Very high. Key risks include: negative DYNE-101 or DYNE-251 clinical data, regulatory delays or rejections, safety signals, competitive pressure from Avidity Biosciences and others, dilution from future equity offerings, and the inherent binary nature of clinical-stage biotech investment. | High |
| AI confidence | High for cash, shares, market cap, and burn rate from SEC filings. Low for pipeline valuation, clinical success probability, and forward price targets. | Medium overall |
| Investment certainty | Low. Dyne is a binary event-driven biotech where the outcome depends on clinical data quality and regulatory decisions that no model can predict with confidence. | Low |
DYN AI stock forecast
The DYN AI stock forecast uses scenario math around the $23.42 cutoff price and Dyne Therapeutics enterprise value of roughly $2.9 billion (market cap minus cash). The three-year framework produced a bearish area near $6 to $10 (pipeline value zero, stock returns to cash value), a base area near $35 to $50, and a bullish area near $65 to $90, depending on DYNE-101 approval and commercial success assumptions.
$65 to $90
More likely if DYNE-101 demonstrates compelling efficacy and safety in the ACHIEVE registrational expansion cohort, leading to FDA approval and robust commercial uptake in the large DM1 market. Positive DYNE-251 data in DMD exon 51 and DYNE-301 progress in FSHD would further support a platform premium.
$35 to $50
More likely if DYNE-101 achieves approval with a moderate label and initial commercial adoption follows a gradual launch curve, DYNE-251 shows proof-of-concept data enabling partnership or advancement, and the company manages dilution and cash burn within reasonable bounds.
$6 to $10
More likely if DYNE-101 fails to meet efficacy endpoints or shows safety concerns in the registrational cohort, regulatory feedback requires additional trials, or competitive therapies from Avidity, Ionis, or Sarepta reach the market first with superior profiles.
DYN AI technical analysis
DYN AI technical analysis shows a strong uptrend as of the July 12, 2026 data cutoff. The stock has rallied more than 180% from its $8.24 52-week low and is trading near $23.42, close to the $25.00 52-week high. The stock sits above all major moving averages with elevated momentum, making it sensitive to news-driven moves in either direction.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $23.42 | Quote near the $23.42 cutoff placed DYN just below its 52-week high of $25.00. |
| Near support | $20 to $21 | The area around $20 to $21 has acted as support during the recent uptrend and aligns with moving average support levels. |
| Deeper support | $15 to $17 | Prior consolidation zone from April to May 2026, representing a significant retracement level if the uptrend reverses. |
| Near resistance | $25.00 | The 52-week high at $25.00 is the immediate psychological and technical resistance. A break above this level would signal trend continuation. |
| Long-term resistance | $30 to $35 | If DYN breaks above $25, the next resistance zone would be the $30 to $35 area, which represents round-number psychological levels. |
| Momentum | RSI likely above 60-65 | Given the sustained rally from $8.24 to near $25, momentum indicators are likely elevated though not necessarily overbought in the context of a strong uptrend. |
| Volume | Average volume near 2.1 million shares | Trading volume has been elevated during the rally, confirming strong investor interest, but can spike sharply on clinical data releases. |
| Volatility | Very high, typical for clinical-stage biotech | DYN is a binary event-driven stock where clinical data releases, regulatory decisions, and partnership announcements can produce 20-50% single-day moves in either direction. |
| Invalidation | Close below $15 | A decisive close below the $15 to $17 support zone would weaken the uptrend structure and suggest a potential trend reversal. |
DYN AI trading strategy
The DYN AI trading strategy is a rules-based research framework for monitoring a clinical-stage neuromuscular biotech stock with a binary catalyst profile. It is not personal advice and should be paired with fresh clinical data, cash runway updates, position sizing appropriate for high-risk biotech, and a defined invalidation level.
DYNE-101 ACHIEVE trial data is the primary catalyst. Watch for top-line efficacy and safety results from the registrational expansion cohort. Positive data with statistical significance on primary endpoints could trigger a substantial re-rating. Negative data or safety concerns would likely produce a sharp decline toward cash value.
Position sizing must account for binary outcomes. A close below $15 or a failed data readout should trigger an exit. Consider using options for defined risk exposure rather than outright common stock.
If DYN breaks above $25 on above-average volume, the uptrend may extend toward $30 to $35. Maintain position as long as price stays above the 50-day moving average, adjusting stops as the trend develops.
A close below $20 or a violation of the 50-day moving average should invalidate the trend-following setup. Biotech gaps can be severe, so avoid over-leveraging.
Track DYNE-101 ACHIEVE trial data timeline and quality, DYNE-251 DELIVER trial progress, DYNE-301 FSHD program advancement, cash burn rate and runway, dilution risk from equity offerings, competitive positioning against Avidity, Ionis, Sarepta, and PepGen, and analyst sentiment shifts.
Reduce or exit if cash runway shortens without a clear funding path, if competitive therapies show superior data, or if management guidance on clinical timelines slips meaningfully.
Investment research summary
Dyne Therapeutics aims to treat muscle diseases by delivering oligonucleotide therapies directly to muscle tissue using its proprietary FORCE platform, which couples antibodies with therapeutic payloads. Patients and physicians pay for disease-modifying therapy in conditions that currently have limited or no treatment options.
The potential moat is based on the FORCE platform technology for targeted muscle delivery. If validated by clinical data, the platform could be applicable across multiple muscle diseases, creating a pipeline-in-a-product opportunity. However, competitors including Avidity Biosciences (AOC platform), Ionis Pharmaceuticals (antisense), and Sarepta Therapeutics (gene therapy) are pursuing overlapping targets, and the ultimate moat depends on clinical differentiation.
The thesis fails if DYNE-101 efficacy is insufficient, safety signals emerge, regulatory path lengthens, competitors reach the market first with better data, cash runs out before commercial revenues materialize, or the platform approach proves less broadly applicable than hoped.
Management has demonstrated clinical execution by completing ACHIEVE trial enrollment and securing expanded non-dilutive financing. Key tests ahead include data quality at readout, regulatory strategy, manufacturing scale-up, commercial preparation, and disciplined capital allocation. The addition of Barry Greene to the board adds industry credibility.
Dyne operates at the intersection of two important trends: the growing understanding of oligonucleotide therapeutics for genetic diseases and the development of targeted delivery technologies to enable tissue-specific treatment. The muscle disease market, particularly DM1 and DMD, represents significant unmet medical need with large patient populations.
At $23.42, the stock prices in meaningful pipeline value of roughly $17.54 per share above net cash per share of ~$5.88. Margin of safety is limited because the premium depends entirely on positive clinical data. The most favorable risk/reward occurs at lower valuations closer to cash value, not near 52-week highs.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| DYN price | $23.42 | Google Finance quote snapshot | July 12, 2026 |
| Market capitalization | $3.87 billion, verified as $23.42 x 165.31 million shares | Yahoo Finance market cap verification | July 12, 2026 |
| Cash and equivalents | $972 million (most recent quarter) | Yahoo Finance balance sheet data | July 12, 2026 |
| Debt facility | Up to $400 million from Hercules Capital (expanded June 2026) | GlobeNewswire press release | July 12, 2026 |
| TTM net loss | -$451.71 million (GAAP) | Yahoo Finance key statistics | July 12, 2026 |
| Shares outstanding | 165.31 million | Google Finance share count | July 12, 2026 |
| Q1 2026 R&D expense | $100.89 million | Google Finance income statement | July 12, 2026 |
| Q1 2026 operating loss | -$125.28 million | Google Finance income statement | July 12, 2026 |
| 52-week range | $8.24 to $25.00 | Google Finance price range | July 12, 2026 |
| Analyst consensus | 9 Buy, 1 Hold, average target $38.25 (range $17 to $50) | Yahoo Finance analyst estimates | July 12, 2026 |
This page is an informational research tool only and is not investment advice, financial advice, or a recommendation to buy or sell DYN stock. Forecast scenarios are based on available public data, technical snapshots, and stated assumptions as of the data cutoff date and may be wrong. Dyne Therapeutics is a clinical-stage biotechnology company with zero revenue, negative earnings, and binary regulatory and clinical risk. Always verify current filings, clinical data, cash runway, risks, and personal suitability before making financial decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
